Ustekinumab in Pediatric Crohn Disease Patients
Authors:
- 1 September 2016
- journal article
- research article
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 63 (3) , 348-351
Abstract
Objectives: We describe the use of ustekinumab for 4 patients with pediatric Crohn disease treated at the Seattle Children's Hospital Inflammatory Bowel Disease Center.Methods: A retrospective chart review was done to identify patients’ clinical data, disease phenotype, treatment history, and laboratory and growth parameters before treatment with ustekinumab and at last follow‐up. Adverse events while on ustekinumab were also recorded.Results: Four adolescent patients with Crohn disease at our center received ustekinumab. All had previously received corticosteroids, methotrexate, azathioprine/6‐mercaptopurine, and both infliximab and adalimumab. Patients had varying disease phenotypes. Ages at ustekinumab initiation were 12, 13, 16, and 17 years. Weight ranged from 40.5 to 57.8 kg, mean 49.5 kg. Two patients showed clinical response and remain on ustekinumab. Two patients discontinued therapy because of continued symptoms and disease complications and required multiple hospitalizations.Conclusions: Ustekinumab was used in 4 children with pediatric Crohn disease with 2 of 4 patients showing clinical response (1 with persistently elevated C‐reactive protein). A prospective study is needed to define its efficacy, safety, and placement in managing pediatric Crohn disease in the future.Keywords
This publication has 19 references indexed in Scilit:
- Inflammatory bowel disease epidemiologyCurrent Opinion in Gastroenterology, 2013
- Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's DiseaseNew England Journal of Medicine, 2012
- Discovery and mechanism of ustekinumabmAbs, 2011
- Differences in phenotype and disease course in adult and paediatric inflammatory bowel disease - a population-based studyAlimentary Pharmacology & Therapeutics, 2011
- Pediatric modification of the Montreal classification for inflammatory bowel diseaseInflammatory Bowel Diseases, 2011
- Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's DiseaseGastroenterology, 2010
- Long-term outcome of maintenance infliximab therapy in children with Crohnʼs diseaseInflammatory Bowel Diseases, 2009
- Diverse Genome-wide Association Studies Associate the IL12/IL23 Pathway with Crohn DiseaseThe American Journal of Human Genetics, 2009
- Natural History of Pediatric Crohn's Disease: A Population-Based Cohort StudyGastroenterology, 2008
- Natalizumab Therapy for Moderate to Severe Crohn Disease in AdolescentsJournal of Pediatric Gastroenterology and Nutrition, 2007